Search clinical trials for: Valsartan

Total 480 results

Boryung Pharmaceutical Co., Ltd
Asan Medical Center; Chonnam National University Hospital; Seoul National University... and other collaborators

Completed

A Valsartan 80 Mg-Referenced, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan 30 mg During 24 Hours in Patients With Mild to Moderate Essential Hypertension

Essential Hypertension

Korea, Republic of
National Institute of Allergy and Infectious Diseases...

Withdrawn

Optimal Treatment for Kidney Disease in HIV Infected Adults

HIV Infections | Kidney Disease

United States
Columbia University
Novartis Pharmaceuticals

Terminated

Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease

Diabetic Nephropathy | Focal Segmental Glomerulosclerosis | IgA Nephropathy | Glomerulonephritis, Membranous | Hypertensive Nephrosclerosis | Proteinuric Kidney Disease | Glomerulopathy (Obesity-associated)

United States
Boehringer Ingelheim

Completed

1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy

Hypertension | Diabetic Nephropathies

Spain, Taiwan, Malaysia, Italy, Portugal, France, Czech Republic, Korea, Republic of, Russian Federation, Denmark, Germany, Slovakia, Ukraine
Charite University, Berlin, Germany
University of Ulm

Completed

Anti-Inflammatory Actions of Valsartan in Patients With Type 2 Diabetes Mellitus

Coronary Artery Disease | Hypertension | Type 2 Diabetes Mellitus

Germany
Boryung Pharmaceutical Co., Ltd
Asan Medical Center; Ulsan University Hospital; Korea University Anam Hospital; Dong-A University and other collaborators

Completed

A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension (fimasartan)

Hypertension

Korea, Republic of
Nara Medical University

Completed

New Angiotensin II Receptor Blocker Azilsartan Study for Stronger Blood Pressure Lowering (NARA)

Hypertension

Japan
University Hospital, Limoges

Withdrawn

Efficacy of Angiotensin Receptor Blocker Following aortIc Valve Intervention for Aortic STenOsis: a Randomized mulTi-cEntric Double-blind Phase II Study (ARISTOTE)

Aortic Valve Stenosis | Transcatheter Aortic Valve Replacement | Hypertrophy, Left Ventricular | Angiotensin Receptor Antagonists | Heart Valve Prosthesis Implantation | Valsartan

France
Boehringer Ingelheim

Completed

MICARDIS® and Valsartan in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring

Hypertension
University of Copenhagen
Hvidovre University Hospital

Completed

Effect of Neprilysin on Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes (NEPT2D)

Type2 Diabetes

Denmark
Novartis

Completed

Efficacy and Safety of Valsartan Versus Amlodipine in Postmenopausal Women With Hypertension

Hypertension

Switzerland
Novartis

Completed

Safety and Efficacy of Valsartan Plus Hydrochlorothiazide and Amlodipine in Hypertensive Patients

Hypertension

Taiwan
Novartis

Completed

Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Fixed Dose Combination in Hypertensive Patients Not Controlled by the Free Combination of an Angiotensin Receptor Blocker Plus Hydrochlorothiazide

Hypertension

Switzerland, Germany
Mayo Clinic
National Institute on Aging (NIA)

Completed

Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction (CNEPi)

Heart Failure With Preserved Ejection Fraction

United States
Norwegian University of Science and Technology
St. Olavs Hospital; Alesund Hospital; Namsos Hospital; Volvat Medisinsk Senter...

Recruiting

Bariatric Surgery and Pharmacokinetics of Valsartan

Obesity, Morbid

Norway
AstraZeneca

Completed

Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation

Opioid-Induced Constipation (OIC)

United States
Mayo Clinic

Recruiting

PDD in Type 2 Diabetes w/wo Diastolic Dysfunction

Diabetes Mellitus, Type 2 | Diastolic Dysfunction

United States
HealthCore-NERI
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM (VANISH)

Hypertrophic Cardiomyopathy

United States, Canada
Stephen J. Teach, MD, MPH
National Institute of Allergy and Infectious Diseases (NIAID)

Recruiting

Omalizumab Before Onset of Exacerbations (OBOE)

Asthma in Children | Atopy | Viral Upper Respiratory Infection

United States
Universidade Federal Fluminense
Rio de Janeiro State Research Supporting Foundation (FAPERJ)

Completed

Antimicrobial Photodynamic Therapy Associated With the Conventional Endodontic Treatment: A Clinical and Microbiological Study

Infection | Dental Pulp Necrosis | Candida | Polymerase Chain Reaction | Photochemotherapy Reaction | Enterococcal Infections
RenJi Hospital

Recruiting

Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease

Obesity | Chronic Kidney Diseases

China
Novartis

Completed

Efficacy and Safety of Valsartan and Amlodipine (± HCTZ) in Adults With Moderate, Inadequately Controlled Hypertension

Hypertension

Germany
Novartis

Completed

VALENCE: Valsartan Versus Atenolol on Exercise Capacity in Hypertensive Overweight Postmenopausal Women

Hypertension

Switzerland, Germany
Vanderbilt University
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Study of Inflammation and Oxidative Stress in Persons Undergoing Dialysis

End Stage Renal Failure on Dialysis | Complication of Hemodialysis

United States
An-Najah National University

Recruiting

Continuing or Discontinuing ACE/ARBs in Patients With Chronic Kidney Disease Undergoing Coronary Angiography

Chronic Kidney Diseases | Ischemic Heart Disease | Contrast-induced Nephropathy

Palestinian Territory, occupied
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD

Pediatric Hypertension With or Without CKD

Belgium, Poland, Italy, Germany, Guatemala, France, Hungary, Brazil, Lithuania
Yonsei University

Completed

Comparison of Beta-blocker Versus Angiotensin Receptor Blocker for Suppression of Aneurysm Expansion in Patients With Small Abdominal Aortic Aneurysm and Hypertension (BASE Trial)

Small Abdominal Aortic Aneurysm

Korea, Republic of
Hospital Moinhos de Vento
Ministry of Health, Brazil; World Stroke Organization

Recruiting

Polipill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt (PROMOTE) (PROMOTE)

Stroke | Cognitive Decline

Brazil
National Cheng-Kung University Hospital
National Science Council, Taiwan

Unknown

Role of Inflammation Factors and Insulin Resistance in Major Depressive Disorder

Major Depressive Disorder

Taiwan
University of Leeds
The Leeds Teaching Hospitals NHS Trust

Completed

Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression

Hypertension | Left Ventricular Hypertrophy

United Kingdom
AstraZeneca

Completed

Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With Normal Renal Function

Renal Impairment

United States
Takeda

Completed

Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension

Hypertension

United States, Mexico, Chile, Peru
Novartis Pharmaceuticals

Completed

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension

Essential Hypertension

Taiwan, Japan, Hong Kong, Thailand, Philippines, China, Korea, Republic of
Kyoto Prefectural University of Medicine

Completed

Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study)

Stroke | Hypertension | Ischemic Heart Disease | Congestive Heart Failure

Japan
Daiichi Sankyo, Inc.

Completed

The Relative Effects of Olmesartan Medoxomil, Irbesartan and Valsartan on the Activity of the Blood Pressure Control System in Healthy Subjects

Healthy
Novartis Pharmaceuticals

Completed

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension

Essential Hypertension

Japan
University Hospital, Basel, Switzerland
University Hospital, Zürich; University Hospital Freiburg; Krebsforschung Schweiz... and other collaborators

Completed

177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer

Thyroid Cancer, Medullary

Switzerland
TSH Biopharm Corporation Limited

Completed

ADDM Study - Amtrel and Co-Diovan in Type 2 Diabetes Mellitus Hypertension Patients With Microalbuminuria

Hypertension | Diabetes Mellitus, Type 2 | Albuminuria

Taiwan
Academisch Ziekenhuis Maastricht
ZonMw: The Netherlands Organisation for Health Research and Development

Recruiting

Timely Recovery After Subclinical Heart Failure (TREASURE)

Heart Failure | Diastolic Dysfunction

Netherlands
Achaogen, Inc.
Department of Health and Human Services

Completed

A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE) (CARE)

Bloodstream Infections (BSI) Due to CRE | Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE | Ventilator-Associated Bacterial Pneumonia (VABP) Due to CRE | Complicated Urinary Tract Infection (cUTI) Due to CRE | Acute Pyelonephritis (AP) Due to CRE
Novartis Pharmaceuticals

Completed

Effect of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children With High Blood Pressure

Hypertension

United States, Hungary, Poland, Turkey, Belgium, France, Germany, India, Italy, Slovakia, Sweden
Takeda

Completed

An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.

Hypertension

United States, Mexico, Peru, Brazil, Argentina, Puerto Rico
Boryung Pharmaceutical Co., Ltd

Completed

Fimasartan Achieving SBP Target (FAST) Study (FAST)

Essential,Hypertension

Korea, Republic of
Novartis Pharmaceuticals

Completed

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension

Essential Hypertension

China, Korea, Republic of, Taiwan, Hong Kong, Thailand, Philippines, Singapore
Novartis

Completed

A Study of VAH631 in Patients With Essential Hypertension (Factorial Study)

Hypertension

Japan
Vanderbilt University Medical Center

Active, not recruiting

Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1

Hypertension

United States
Assistance Publique - Hôpitaux de Paris

Completed

Effects of Sodium Intake on (PK/PD) Relationship of a Single Dose of a Renin Angiotensin System-Blocker

Healthy

France
Cheng-Hsin General Hospital

Completed

Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy

Heart Failure | Hypotension

Taiwan
Novartis Pharmaceuticals

Completed

Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.

Chronic Heart Failure With Reduced Ejection Fraction

Germany
Novartis

Completed

Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome (LesScore)

Hypertension, Dyslypidaemia

Search clinical trials for: Valsartan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations